Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMWEH6)

• Drug Name: AVP-21D9 Drug Info
• Synonyms: Thravixa; AVP-1C6; AVP-22G12; AVP-8C1; Anthrax antibody, AVANIR; Anthrax toxin Mab, Xenerex; Protective antigen-targeting human monoclonal antibodies (intravenous, anthrax), AVANIR; Protective antigen-targeting human monoclonal antibodies (intravenous, anthrax), Emergent

Indication

Disease Entry	ICD 11	Status	REF
Bacillus anthracis infection	1G40	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMMWEH6

Molecule-Related Drug Atlas

Drug(s) Targeting Bacterial Protective antigen (Bact pagA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Raxibacumab	DM7QG0M	Anthrax	1B97	Approved	[3]
IQ-DAA	DMHP71R	Bacillus anthracis infection	1G40	Phase 1	[4]
Valortim	DMYAIUB	Bacterial infection	1A00-1C4Z	Phase 1	[5]
Anthrax vaccine	DM9GSWY	Bacillus anthracis infection	1G40	Discontinued in Phase 1	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Protective antigen (Bact pagA)	TT3YGCD	PAG_BACAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT01202695) Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9). U.S. National Institutes of Health.
• [2] Efficacy and Safety of AVP-21D9, an Anthrax Monoclonal Antibody, in Animal Models and Humans. Antimicrob Agents Chemother. 2014 July; 58(7): 3618-3625.
• [3] Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43.
• [4] Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol.2009 Feb;4(1):35-43.
• [5] Phase I Study Evaluating the Safety and Pharmacokinetics of MDX-1303, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers. Clin Vaccine Immunol. 2011 December; 18(12): 2136-2142.
• [6] Annual Reports in Medicinal Chemistry. Annette M. Doherty. 2005. Page(214).